Cargando…
干扰FOXC1逆转非小细胞肺癌吉非替尼耐药的作用
BACKGROUND AND OBJECTIVE: Lung cancer is the malignant tumor with the highest incidence and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for about 80%. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy has been playing an important...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387653/ https://www.ncbi.nlm.nih.gov/pubmed/34334155 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.103.11 |